目的:检测多囊卵巢综合征(PCOS)患者妊娠母血及脐血中胰岛素样生长因子-1(IGF-1)水平,判定IGF-1与PCOS患者妊娠结局的关系,探讨IGF-1是否可作为PCOS妊娠患者诊断标记物. 方法:收集2012年1月至2013年12月本院120例PCOS患者妊娠母血及脐血作为PCOS组, 同期收集无PCOS史120例的正常孕产妇妊娠母血及脐血作为对照组,ELISA法检测IGF-1水平,并对两组患者不同妊娠结局进行分析. 结果:PCOS 组妊娠母血及脐血中IGF-1的水平均显著上升,与对照组相比,差异有统计学意义(P < 0.05). PCOS 组患者妊娠结局死胎、早产、巨大儿发生率均显著高于对照组(P < 0.05); PCOS组所有妊娠结局不良患者妊娠母血及脐血中IGF-1均显著高于对照组(P < 0.05). 结论:IGF-1可作为PCOS患者妊娠结局风险预测标记物.%Objective To detect the effect of insulin-like growth factor-1 (IGF-1) at varied levels in pregnancy maternal serum and cord serum of patients with the polycystic ovary syndrome (PCOS) on pregnancy outcomes, and explore whether IGF-1 could be used as a diagnostic marker for PCOS. Methods From January 2012 to December 2013, pregnancy maternal and cord serums were collected from 120 PCOS patients and 120 normal pregnant women in the Department of Obstetrics and Gynecology of our hospital. ELISA was used to detect the levels of IGF-1, and analyze the levels of IGF-1 in different pregnancy outcomes between normal pregnant women and PCOS patients. Results Compared with the control group, the levels of IGF-1 in pregnancy maternal and cord blood were increased significantly in patients with PCOS (P< 0.05). The incidence of stillbirth, premature delivery and macrosomia was significantly higher in PCOS patients. The levels of IGF-1 in pregnancy maternal and cord serum were significantly higher in all PCOS patients with adverse pregnancy outcomes compared with the control group (P < 0.05). Conclusion IGF-1 could be used as a risk prediction marker for pregnancy outcome in patients with PCOS.
展开▼
